--Dr. Eliasson brings two decades of global biotechnology experience as a leader in integrating innovative technology capabilities with drug development--
LOS ALTOS, Calif., April 12, 2022 – Alto Neuroscience today announced the expansion of the company’s leadership team with the addition of Mikael Eliasson, M.D., Ph.D., as chief operating officer (COO). Dr. Eliasson brings decades of experience in drug development to support the advancement of Alto’s business operations and clinical development strategy.
“Dr. Eliasson’s extensive career working across top global pharmaceutical companies, with deep experience in R&D and commercial operations across healthcare business models, will be invaluable to our team,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto. “His expertise in scaling emerging technologies and building next-generation healthcare companies will support Alto’s next phase of growth as we continue to advance the largest clinical-stage pipeline in precision psychiatry. I look forward to working closely with Mikael to apply the full potential of our platform to help patient populations experiencing great unmet need.”
Dr. Eliasson is a trained physician-scientist with over 20 years of experience driving corporate strategy and innovation, leading the transformation of biotechnology companies into multi-billion-dollar businesses across diversified portfolios. Prior to joining Alto, Dr. Eliasson led global teams at Genentech/Roche responsible for piloting and scaling technology capabilities into drug development. This included Roche’s first digital therapeutic, its first health-authority validated digital endpoint, and efforts in precision psychiatry. Prior, Dr. Eliasson served as global head of new products at Novartis where he championed its entry into heart failure and the development of Entresto®. Dr. Eliasson has also held roles at The Medicines Company, Monitor Group, and GE Healthcare.
“I am thrilled to join Alto, a team of talented and dedicated individuals, and I am deeply passionate about our mission to use technology to bring precision medicine to the many people with mental health conditions who need better treatment options,” added Dr. Eliasson. “I believe Alto’s platform, strategy and data-driven approach will provide us with the tools necessary to achieve this goal. I look forward to applying my background to accelerate and scale Alto’s operations in a meaningful way, further transforming psychiatric drug development and maximizing impact for patients.”
Dr. Eliasson was a neurosurgical resident at Boston Children’s Hospital as well as Brigham and Women’s Hospital. Dr. Eliasson earned his M.D. and Ph.D. from The Johns Hopkins University School of Medicine and his BA in biochemical sciences from Harvard College.
About Alto Neuroscience
Alto Neuroscience is pioneering precision psychiatry by developing targeted medicines to help patients get better faster. Differences in individuals’ biology impact how they respond to treatment. Alto’s human data-driven platform measures brain biomarkers including EEG activity and behavioral patterns, wearable data, genetics, and other factors, to match each patient with the right Alto therapy. The company’s clinical-stage pipeline includes drug candidates being studied in mental health conditions targeting cognition, emotion, and sleep processes. For more information, visit https://www.altoneuroscience.com or follow us on Twitter.